A multiscale mathematical model for oncolytic virotherapy.

One of the most promising strategies to treat cancer is attacking it with viruses. Oncolytic viruses can kill tumor cells specifically or induce anticancer immune response. A multiscale model for virotherapy of cancer is investigated through simulations. It was found that, for intratumoral virus administration, a solid tumor can be completely eradicated or keep growing after a transient remission. Furthermore, the model reveals undamped oscillatory dynamics of tumor cells and virus populations, which demands new in vivo and in vitro quantitative experiments aiming to detect this oscillatory response. The conditions for which each one of the different tumor responses dominates, as well as the occurrence probabilities for the other nondominant therapeutic outcomes, were determined. From a clinical point of view, our findings indicate that a successful, single agent virotherapy requires a strong inhibition of the host immune response and the use of potent virus species with a high intratumoral mobility. Moreover, due to the discrete and stochastic nature of cells and their responses, an optimal range for viral cytotoxicity is predicted because the virotherapy fails if the oncolytic virus demands either a too short or a very large time to kill the tumor cell. This result suggests that the search for viruses able to destroy tumor cells very fast does not necessarily lead to a more effective control of tumor growth.

[1]  F. Khuri,et al.  Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Swisher,et al.  Redirecting adaptive immunity against foreign antigens to tumors for cancer therapy , 2007, Cancer biology & therapy.

[3]  R. Jain,et al.  Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. , 2008, Cancer research.

[4]  R. Weinberg,et al.  The Biology of Cancer , 2006 .

[5]  M. Gulley,et al.  A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  M. L. Martins,et al.  Reaction-diffusion model for the growth of avascular tumor. , 2001, Physical review. E, Statistical, nonlinear, and soft matter physics.

[7]  M. L. Martins,et al.  Morphology transitions induced by chemotherapy in carcinomas in situ. , 2002, Physical review. E, Statistical, nonlinear, and soft matter physics.

[8]  M. Coffey,et al.  Reovirus therapy of tumors with activated Ras pathway. , 1998, Science.

[9]  M. L. Martins,et al.  Multiscale models for the growth of avascular tumors , 2007 .

[10]  M. Magnusson,et al.  An oncolytic adenovirus redirected with a tumor-specific T-cell receptor. , 2007, Cancer research.

[11]  M. Coffey,et al.  Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial , 2008, Gene Therapy.

[12]  R. Hill,et al.  E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models , 2003, Nature Biotechnology.

[13]  Y. Chen,et al.  The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. , 1999, Cancer research.

[14]  S K Baird,et al.  Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer , 2008, Oncogene.

[15]  E. Galanis,et al.  Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress , 2007, Nature Clinical Practice Oncology.

[16]  L. Wein,et al.  Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response , 2004, Bulletin of mathematical biology.

[17]  S. Russell,et al.  Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model , 2006, Cancer Gene Therapy.

[18]  J. Foloppe,et al.  Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus , 2008, Gene Therapy.

[19]  L. Eisenlohr,et al.  Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma , 1999, Cancer Gene Therapy.

[20]  W. Rom,et al.  Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  D. Wodarz,et al.  Viruses as antitumor weapons: defining conditions for tumor remission. , 2001, Cancer research.

[22]  G. Milton,et al.  The limited role of attenuated smallpox virus in the management of advanced malignant melanoma. , 1966, The Australian and New Zealand journal of surgery.

[23]  Lawrence M Wein,et al.  Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. , 2003, Cancer research.

[24]  Vasilis Ntziachristos,et al.  Shedding light onto live molecular targets , 2003, Nature Medicine.

[25]  G. Barber,et al.  Genetically Engineered Vesicular Stomatitis Virus in Gene Therapy: Application for Treatment of Malignant Disease , 2002, Journal of Virology.

[26]  J. Bell,et al.  Recent progress in the battle between oncolytic viruses and tumours , 2005, Nature Reviews Cancer.

[27]  M. L. Martins,et al.  Fighting cancer with viruses , 2005 .

[28]  E. Chiocca,et al.  Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. , 1998, Annals of surgery.

[29]  川島 健 Telomerase-specific replication-selective virotherapy for human cancer , 2004 .

[30]  F. Khuri,et al.  Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. , 2000, Cancer research.